Phathom Pharmaceuticals (PHAT) stock is surging 8.41% in early trading on Friday, building on its pre-market momentum following the release of its third-quarter 2025 earnings report and a positive analyst update. The biopharmaceutical company's shares are gaining significant traction as investors react to the latest financial results and revised market outlook.

The company's Q3 earnings release, which came out late Thursday, appears to have impressed investors with strong growth figures. While specific details of the report are limited, the market's reaction suggests that Phathom Pharmaceuticals' performance likely exceeded expectations, driving the stock's upward trajectory.

Adding fuel to the rally, H.C. Wainwright raised its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects. This substantial 30% increase in the price target reflects the analyst's bullish outlook on Phathom's potential. Furthermore, HC Wainwright & Co. has maintained its "Buy" rating on the stock, reinforcing the positive sentiment surrounding the company.

The combination of strong quarterly results and analyst optimism has created a perfect storm for Phathom Pharmaceuticals' stock, propelling it to significant gains as the market opens. This surge demonstrates investors' enthusiasm for the company's performance and their expectations for continued growth in the biopharmaceutical sector.